Page last updated: 2024-08-21

indazoles and Adrenocortical Carcinoma

indazoles has been researched along with Adrenocortical Carcinoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Balasubramaniam, S; Edgerly, M; Fojo, T; Nguyen, D; O'Sullivan, C; Pittaluga, S; Velarde, M; Venkatesan, AM; Wilkerson, J; Yang, SX	1

Trials

1 trial(s) available for indazoles and Adrenocortical Carcinoma

Article	Year
The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:4 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Angiogenesis Inhibitors; Axitinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Indazoles; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A	2014

Article

Year

The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.

The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:4

Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Angiogenesis Inhibitors; Axitinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Indazoles; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A

2014